Paratek Pharmaceuticals Revenue vs. Return On Asset

PRTKDelisted Stock  USD 2.18  0.00  0.00%   
Based on Paratek Pharmaceuticals' profitability indicators, Paratek Pharmaceuticals may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Paratek Pharmaceuticals' ability to earn profits and add value for shareholders.
For Paratek Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Paratek Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Paratek Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Paratek Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Paratek Pharmaceuticals over time as well as its relative position and ranking within its peers.
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Please note, there is a significant difference between Paratek Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Paratek Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Paratek Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Paratek Pharmaceuticals Return On Asset vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Paratek Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Paratek Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Paratek Pharmaceuticals is rated top company in revenue category among its peers. It is regarded fourth in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Paratek Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Paratek Revenue vs. Competition

Paratek Pharmaceuticals is rated top company in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 280.96 Million. Paratek Pharmaceuticals totals roughly 150.79 Million in revenue claiming about 54% of equities under Health Care industry.

Paratek Return On Asset vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Paratek Pharmaceuticals

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
150.79 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Paratek Pharmaceuticals

Return On Asset

 = 

Net Income

Total Assets

 = 
-0.18
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.

Paratek Return On Asset Comparison

Paratek Pharmaceuticals is currently under evaluation in return on asset category among its peers.

Paratek Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Paratek Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Paratek Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Paratek Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Paratek Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts. Paratek Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 207 people.

Paratek Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Paratek Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Paratek Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Paratek Pharmaceuticals' important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in Paratek Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Sync Your Broker Now

   

Sync Your Broker

Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
All  Next Launch Module

Use Investing Themes to Complement your Paratek Pharmaceuticals position

In addition to having Paratek Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Consumer Goods Thematic Idea Now

Consumer Goods
Consumer Goods Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Consumer Goods theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Goods Theme or any other thematic opportunities.
View All  Next Launch
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Other Consideration for investing in Paratek Stock

If you are still planning to invest in Paratek Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Paratek Pharmaceuticals' history and understand the potential risks before investing.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Bonds Directory
Find actively traded corporate debentures issued by US companies
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world